Blacksburg biotech company Landos Biopharma Inc. has gone public.

An initial public offering of stock, priced at $16 a share, was expected to raise $100 million to develop possible new treatments for autoimmune diseases.

The Landos labs at the Virginia Tech Corporate Research Center have “identified seven novel immunometabolic targets and product candidates” for the treatment of such ailments as ulcerative colitis, Crohn’s disease, lupus, rheumatoid arthritis, multiple sclerosis, Alzheimer’s disease, asthma, psoriasis, chronic obstructive pulmonary disease and type 1 diabetes.

Those descriptions and scores of scientific charts have been filed by Landos with the U.S. Securities and Exchange Commission.

Click here to read more via The Roanoke Times.

The following two tabs change content below.